BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Nagai K, Nakagawa T, Sugawara T, Hanaoka H, Kanai F, Yokosuka O. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology 2018;67:575-85. [PMID: 28746788 DOI: 10.1002/hep.29403] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
2 Zhang Y, Jiang L, Wen J, Liu D, Huang G, Wang Y, Fan W, Li J. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2018;29:1654-61. [DOI: 10.1016/j.jvir.2018.07.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
3 Meyer T, Palmer DH, Cheng A, Hocke J, Loembé A, Yen C. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017;37:1047-55. [DOI: 10.1111/liv.13359] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
4 Hao MZ, Lin HL, Chen QZ, Hu YB, Chen JB, Zheng JX, Zhou D, Zhang H. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma. J Dig Dis 2017;18:31-9. [PMID: 27987344 DOI: 10.1111/1751-2980.12435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Mähringer-Kunz A, Weinmann A, Schmidtmann I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C, Galle PR, Kloeckner R. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer 2018;18:489. [PMID: 29703174 DOI: 10.1186/s12885-018-4407-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jin Z, Chen L, Zhong B, Zhou H, Zhu H, Zhou H, Song J, Guo J, Zhu X, Ji J, Ni C, Teng G. Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. Transl Oncol 2021;14:101034. [PMID: 33567388 DOI: 10.1016/j.tranon.2021.101034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Li JR, Wu MJ, Wang T, Tian M, Zhou G, Liu QX, Xiang XH, Zhang YQ. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. Abdom Radiol (NY) 2021;46:1967-76. [PMID: 33386450 DOI: 10.1007/s00261-020-02897-6] [Reference Citation Analysis]
9 Zhang ZS, Li HZ, Ma C, Xiao YD. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer 2019;19:1162. [PMID: 31783814 DOI: 10.1186/s12885-019-6386-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. J Gastroenterol Hepatol. 2017;32:487-496. [PMID: 27503585 DOI: 10.1111/jgh.13501] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
11 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015;10:e0133488. [PMID: 26230853 DOI: 10.1371/journal.pone.0133488] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
12 Ye Z, Deng Z, Jiang S, Wang T, Liu L, Jiang K, Zhang Y. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy. Cardiovasc Intervent Radiol 2021;44:1394-402. [PMID: 33948697 DOI: 10.1007/s00270-021-02846-w] [Reference Citation Analysis]
13 Newell PH, Wu Y, Hoen H, Uppal R, Thiesing JT, Sasadeusz K, Cassera MA, Wolf RF, Hansen P, Hammill CW. Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival. HPB (Oxford) 2015;17:454-60. [PMID: 25580988 DOI: 10.1111/hpb.12377] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Wang W, Zhao Y, Bai W, Han G. Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue. J Hepatol. 2015;63:1530-1531. [PMID: 26256436 DOI: 10.1016/j.jhep.2015.07.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
15 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
16 Lionço LC, de Mattos AA, Horbe AF, Costabeber AM, de Mattos ÂZ, Tarasconi DP. Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. Eur J Gastroenterol Hepatol 2017;29:225-30. [PMID: 27759574 DOI: 10.1097/MEG.0000000000000764] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Patel T, Harnois D. Assessment of response to therapy in hepatocellular carcinoma. Ann Med 2014;46:130-7. [PMID: 24716738 DOI: 10.3109/07853890.2014.891355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Bartnik K, Hołówko W, Rowiński O. Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. Life (Basel) 2021;11:1062. [PMID: 34685433 DOI: 10.3390/life11101062] [Reference Citation Analysis]
19 Hasdemir DB, Dávila LA, Schweitzer N, Meyer BC, Koch A, Vogel A, Wacker F, Rodt T. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol 2017;23:217-22. [PMID: 28256449 DOI: 10.5152/dir.2016.16006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Dai Y, Jiang H, Feng S, Xia Y, Li J, Zhao S, Wang D, Zeng X, Chen Y, Xin Y, Liu D. Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. JHC 2022;Volume 9:273-88. [DOI: 10.2147/jhc.s351077] [Reference Citation Analysis]
21 Haywood N, Gennaro K, Obert J, Sauer PF Jr, Redden DT, Zarzour J, Smith JK, Bolus D, Saddekni S, Aal AK, Gray S, White J, Eckhoff DE, DuBay DA. Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? J Oncol 2016;2016:4692139. [PMID: 26949394 DOI: 10.1155/2016/4692139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]